Drugs / Apitolisib
Apitolisib
also known as
GDC-0980 · APITOLISIB (GDC-0980) · G-038390 · G-038390.1 · GDC-0980 (RG7422) · GDC-0980.1 · GNE 390 · RG 7422
Small molecule targets MTOR via inhibition
Trials 11 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 18 trials | ||||||
| Phase 1 | NCT01487239 | Dec 2011 → Jan 2012 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01473316 | Nov → Dec 2011 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01301716 | Sep 2011 → Aug 2014 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01332604 | Jul 2011 → Jun 2015 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01254526 | Dec 2010 → Jul 2012 | breast cancer | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01287091 | Oct 2010 → Feb 2011 | — | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00854126 | May 2009 → Jul 2012 | non-Hodgkin lymphoma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00854152 | Mar 2009 → Nov 2014 | non-Hodgkin lymphoma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01455493 | Dec 2011 → Mar 2013 | endometrial carcinoma | Genentech, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01437566 | Oct 2011 → Apr 2016 | breast cancer | Genentech, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01442090 | Oct 2011 → May 2013 | renal cell carcinoma | Genentech, Inc. | Completed | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 12 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Apitolisib | “Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With...” PMID 26951309 ↗ Mar 2016 |
| Known as | APITOLISIB (GDC-0980) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1922094 ↗ |
| Known as | G-038390 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1922094 ↗ |
| Known as | G-038390.1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1922094 ↗ |
| Known as | GDC-0980 | “Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With...” PMID 26951309 ↗ Mar 2016 |
| Known as | GDC-0980 (RG7422) | ChEMBL registry synonym — accepted as the source's own label CHEMBL1922094 ↗ |
| Known as | GDC-0980.1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1922094 ↗ |
| Known as | GNE 390 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1922094 ↗ |
| Known as | RG 7422 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1922094 ↗ |
| Action | Inhibit | “dual inhibition of PI3K/mammalian target of rapamycin (mTOR) by apitolisib (GDC-0980)” PMID 26951309 ↗ Mar 2016 |
| Modality | Small molecule | — CHEMBL1922094 ↗ |
| Route | Oral | “escalating oral doses of GDC-0980 administered” NCT00854126 ↗ |
| Target | MTOR | “inhibition of PI3K/mammalian target of rapamycin (mTOR) by apitolisib (GDC-0980)” PMID 26951309 ↗ Mar 2016 |